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Abstract Orphanin FQ2 (OFQ2) is a novel heptadecapeptide
generated from prepronociceptin (PPNOC), the same precursor
of nociceptin/orphanin FQ and nocistatin. OFQ2 is a potent
analgesic when administered both supraspinally and spinally. In
order to clarify the structural relationship with all peptides
generated from PPNOC, we have undertaken the conformational
study of OFQ2 in water and in structure-promoting solvent
media. Nuclear magnetic resonance data and theoretical
calculations are consistent with a well defined helical structure
from Met5 to Ser16. The uniform distribution of hydrophobic
residues along the helix suggests that OFQ2 may interact with
the transmembrane helices of a receptor akin to those of
nociceptin and opioids.
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1. Introduction
Nociceptin/orphanin FQ (FGGFTGARKSARKLANQ,
henceforth called NC) and orphanin FQ2 (FSEFMRQY-
LVLSMQSSQ) (OFQ2) are two biologically active heptadeca-
peptides processed from the same precursor, prepronociceptin
(PPNOC) [1^3]. Both have an N-terminal sequence character-
ized by two aromatic residues spaced by two residues remi-
niscent of the message domain of the well known opioid hep-
tadecapeptide dynorphin A (YGGF). Recently, it has been
reported [3] that bovine PPNOC contains another biologically
active heptadecapeptide named nocistatin. Bovine nocistatin,
TEPGLEEVGEIEQKQLQ, plays a role opposite to that of
nociceptin in pain transmission but it is not related in any
obvious way to known opioid peptides. Both the sequence
of the message domain and the conformational behavior sug-
gest a structure^activity relationship di¡erent from those of
dynorphin A and nociceptin. In opioids and nociceptin, the
message domains are the N-terminal part (YGGF and FGGF,
respectively), whereas the shortest fragment of nocistatin that
retains allodynia-blocking activity is the C-terminal hexapep-
tide (EQKQLQ), which is conserved in bovine, human and
murine species. Dynorphin A [4] and nociceptin [5] show little
tendency to form well de¢ned structures in solution, not only
in water and other polar solvents, but also in helix-inducing
media. Nocistatin, on the other hand, forms a well de¢ned
structure extending from Gly4 to Leu16, with an unusually
well de¢ned helix (for a short peptide) in the C-terminal
part [6].
NC is an endogenous ligand for the opioid receptor-like 1
(ORL1). Activation of this receptor by NC involves many
physiological functions, both in the periphery and in the cen-
tral nervous system [7,8]; in particular, NC evokes hyperalge-
sia and anti-opioid e¡ects in the brain and analgesia in the
spinal cord [9]. Nocistatin blocks NC-induced allodynia and
hyperalgesia and attenuates pain evoked by prostaglandin E2
[3]. OFQ2 was tested for its ability to activate or to bind to
the ORL1 receptor expressed in CHO cells and in mouse
brain homogenates. It was found unable to displace 125I-
Tyr14-NC binding on membranes of ORL1 receptor-trans-
fected CHO cells and to induce an inhibition of forskolin-
stimulated cAMP at concentrations up to 10 WM [5]. In com-
petition binding studies, OFQ2 showed IC50 values larger
than 1 WM against all the traditional opioid receptors and
did not compete with NC^radioligand binding in mouse brain
homogenates [5]. However, Pasternak et al. [12] reported that
OFQ2 is a potent analgesic given either supraspinally or spi-
nally, and while supraspinal OFQ2 analgesia is readily re-
versed by naloxone, implying activation of opioid receptor
systems, spinal OFQ2 analgesia is insensitive to opioid antag-
onists. Moreover, the existence of a speci¢c receptor for
OFQ2 has recently been demonstrated by Florin et al. [11].
The di¡erences in biological role, together with the men-
tioned conformational preferences of dynorphin A [4], NC [5]
and nocistatin [6] prompted a detailed conformational study
of OFQ2. Determination of the conformational state in solu-
tion of the OFQ2 may shed light on the proposed role of this
new peptide in pain transmission and on the type of interac-
tion with di¡erent hitherto unknown receptors. OFQ2 was
thus studied in solution conditions similar to those employed
for the other PPNOC peptides. The best structuring condi-
tions were found in hexa£uoroacetone trihydrate (HFA)/
water (50:50, v/v) at 300 K.
2. Materials and methods
2.1. Peptide synthesis and analytical determinations
OFQ2 was synthesized according to published methods using stand-
ard solid-phase synthesis techniques [12]. Protected amino acids and
chemicals were purchased from Bachem, Novabiochem or Fluka
(Switzerland). The resin (4-hydroxymethylphenoxyacetic acid) on the
polyethyleneglycol/polystyrene support, loaded with NK:-Fmoc-
NQ :(Trt)-Gln (Fmoc-Gln(Trt)-PAC-PEG-PS) was from Millipore
0014-5793 / 00 / $20.00 ß 2000 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 0 0 ) 0 1 5 1 3 - 1
*Corresponding author. Fax: (39)-81-8534236.
E-mail: ttancredi@icmib.na.cnr.it
FEBS 23646 8-5-00
FEBS 23646 FEBS Letters 473 (2000) 157^160
(Waltham, MA, USA). The protected peptide^resin was treated with
tri£uoroacetic acid (TFA)/water/triethylsilane 88/5/7 (10 ml/0.2 g of
resin) for 1 h at room temperature, crude peptide was puri¢ed by
preparative reversed-phase high performance liquid chromatography
(HPLC) on a column C18 (30U4 cm, 300 Aî , 15 Wm spherical particle
size) perfused at a £ow rate of 40 ml/min with a mobile phase con-
taining solvent A (10%, v/v, acetonitrile in 0.1% TFA), and a linear
gradient from 10 to 60% of solvent B (60%, v/v, acetonitrile in 0.1%
TFA).
Analytical HPLC analyses were performed on a Alltech column C18
(4.6U150 mm, 5 Wm particle size) using the above solvent system
programmed at a £ow rate of 1 ml/min with a linear gradient from
0% to 80% B in 25 min.
Molecular weights of the compounds were determined by a matrix-
assisted laser desorption ionization time of £ight analysis using a
Hewlett Packard G2025A LD-TOF system mass spectrometer and
K-cyano-4-hydroxycinnamic acid as a matrix.
2.2. Nuclear magnetic resonance (NMR) experiments
NMR sample was prepared by dissolving appropriate amounts of
peptide in 0.5 ml of solvents to make approximately 2 mM solutions.
All spectra were run at 300 K on a Bruker DRX-500 instrument,
operating at 500 MHz for 1H. All chemical shifts, in parts per million,
are referred to the methyl resonance of TMS or TSP. One dimensional
NMR spectra were acquired using 32 scans with 32k data size. Two
dimensional TOCSY [13] and NOESY [14] spectra were recorded by
using the time-proportional phase incrementation of the ¢rst pulse
[15], with water suppression by presaturation. A TOCSY spectrum
was collected with a mixing time of 50 ms, using the clean MLEV-
17 mixing scheme [13]. NOESY spectra were recorded with mixing
times of 80, 100 and 120 ms. Data processing and analysis were
performed with standard Bruker software (XwinNMR, AURELIA)
and NMRView [16].
2.3. Structure calculations
NOESY cross-peaks from 100 ms spectrum were integrated using
NMRView and translated into interatomic distances using CALIBA,
a routine of DYANA [17]. The structure calculations were performed
using both DYANA and the AMBER 5.0 package [18].
2.3.1. Structure calculations with AMBER 5.0. The calculations
were performed using the AMBER all-atom 1991 parameterization,
with a distance dependent dielectric constant O= rij, and a cuto¡ ra-
dius of 8 Aî for non-bonded interactions. Two sets of initial structures
were generated, using the standard residue charges and reduced net
charges ( þ 0.2 atomic units) on charged residues, respectively. This
second set is useful for in vacuo simulations, in order to compensate
in part for neglect of explicit solvent. Energy minimizations (EM)
were performed by a combination of steepest descent and conjugate
gradient algorithms, to a gradient norm of 1034 kcal/mol/Aî .
Each set of EM initial structures underwent two di¡erent multiple
restrained simulated annealings (SA). In both cases, SA cycles of ¢ve
runs of 50 000 molecular dynamics (MD) steps were run, but a shorter
time step was chosen (0.0015 vs. 0.0020 ps) in higher maximum tem-
perature (1200 K) runs. Distance restraints were applied by a square
bottom with parabolic sides penalty function, and a force constant of
20 kcal/mol/Aî . Data were collected each 500 steps for analysis. 50
periodically selected structures were chosen from each SA cycle, and
minimized to represent the solution structure.
2.3.2. Structure calculations with DYANA. A set of structures was
generated by DYANA [17] by torsion angle dynamics. A total of 60
structures were calculated by SA, starting with a total of 4000 MD
steps and default values of temperature and time steps. The best 50
structures in terms of target function were re¢ned by EM with the
SANDER module of AMBER 5.0 and selected to represent the solu-
tion structure. All the structures were analyzed with the program
MOLMOL [19], also used to plot Figs. 3 and 4a,b.
3. Results
OFQ2 is virtually insoluble in water and neat DMSO and
has a very small solubility in a mixture of water with DMSO.
Spectra of OFQ2 in the DMSO/water cryomixture, however,
are not of su⁄cient quality to yield detailed structural infor-
mation. On the contrary, media that are known to favor hel-
ical conformations show NOESY spectra consistent with a
high helical content. Alcohols, either neat or mixed with
water, have often been used to induce helicity in peptides
[20]. We ran spectra of OFQ2 in mixtures of water with
TFE and HFA. This last mixture has recently been shown
to behave like TFE/water mixtures but with a much higher
helix-inducing propensity [21]. We have also shown that the
structuring e¡ect of HFA/water, although very strong, re£ects
intrinsic residue tendencies faithfully. In fact, it is possible to
observe structured and unstructured tracts in the same peptide
dissolved in HFA/water. For instance, L-endorphin, another
long-chain opioid, in HFA/water assumes a regular helical
structure only in the C-terminal address domain sequence,
leaving the ¢rst 12 residues completely disordered [22].
Assignment of proton spin systems was obtained with the
sequential methodology. In the NH^NH region of a NOESY
spectrum, it is possible to follow the connectivities from Glu3
to Ser16 with only few interruptions due to cross-peak overlap
in the region from Leu11 to Gln14. Several attempts to elim-
inate this overlap, either running spectra at di¡erent temper-
atures or solvent mixtures (e.g. DMSO/water), were unsuc-
cessful. The solution structure of OFQ2 was delineated from
quantitative analysis of the sequential and medium-range
NOEs. Fig. 1 shows the summary of diagnostic NOEs in
HFA/water at 300 K and 100 ms mixing time. The strong
NHi^NHi1 NOEs (from Glu3 to Ser16) and the correspond-
ing weaker CKHi^NHi1 NOEs are features typical of helical
structures. The observations of several unambiguous medium-
range NOEs, from Met5 to Gln14, are also in favor of the
presence of an helix in this peptide region. Distance restraints
deriving from intraresidue, sequential and medium-range
NOEs were introduced in SA calculations performed with
both AMBER 5.0 and DYANA packages.
For both the AMBER and DYANA SA/EM structure cal-
culation procedures (see Section 2), the best 45 structures in
terms of minimal root mean square (RMS) deviation were
selected from the 50 structures periodically chosen in each
SA/EM cycle. Fig. 2 shows the corresponding energies and
global RMS deviations for both sets of structures. The SA/
EM structures from AMBER calculations do always show
lower energies and better values of the RMS deviations than
the corresponding DYANA SA/EM structures, suggesting a
direct in£uence of the molecular mechanics force ¢eld on the
results. Fig. 3 shows a superposition of the peptide backbone
for the 45 best structures of OFQ2 as obtained from AMBER
Fig. 1. Diagrammatic representation of sequential and secondary
structural interresidue NOEs (dm = 100 ms) observed for OFQ2 in
HFA/water (50% v/v) at 300 K.
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SA/EM and DYANA SA/AMBER EM, respectively, where
the AMBER structures are those obtained with reduced
charges on the ionizable groups. While for the AMBER SA/
EM structures, a well de¢ned helical region, ranging from Ser2
to Ser16, can be observed, the DYANA SA/EM structures do
show an helical structure only from Met5 to Ser16, leaving the
N-terminal tetrapeptide out of the helix. In fact, the NMR
experimental support for a helical structure, i.e. the presence
of medium-range interresidue NOEs, is only observed from
Met5 onwards.
The observation of a shorter helix length and larger devia-
tions from an ideal helix in the structures derived from DYA-
NA SA calculations could be ascribed to:
1. A net attenuation of all the observed NOESY cross-peak
intensities, due to instrumental and/or experimental fea-
tures. If such is the case, DYANA SA would lead to larger
variations for the complete peptide due to the scarcity of
constraints in some regions of the peptide (i.e. from Phe1 to
Met5); AMBER force ¢eld, on the other hand, could be
able to construct a larger helix starting from a well de¢ned
helical nucleus.
2. A conformational equilibrium between all-helical and par-
tially helical structures. DYANA SA protocol, which
works in a straightforward manner when the set of con-
straints is complete, would give a description of this con-
formational equilibrium, whereas AMBER force ¢eld
would lead in any case to an all-helical structure.
Fig. 4 presents a plot of two views of OFQ2 with hydro-
Fig. 2. Energies and global RMS deviations for the best 45 struc-
tures of each SA/EM cycle. The following nomenclature was used
to designate each SA/EM cycle: ext (SA/EM cycle performed with
AMBER 5.0, on an initial extended geometry); ext_nmr (same as
previous but the net charge on charged residue chains is reduced, in
this case, to þ 0.2); ext_nmr_ht (same as the previous one but the
annealing was run at higher temperatures); dyana (SA performed
with DYANA and EM with AMBER 5.0).
Fig. 3. Cylindrical surrounding of the best structures of OFQ2 ob-
tained from AMBER SA/EM (left upper one) and DYANA SA/
AMBER EM (left lower one). ‘Cylinders’ were obtained by a least
square ¢t of a cylinder surface to the atoms. The ‘cylinder radius’ is
a measure of the global RMS deviation in the corresponding region
of the peptide. The right part of the ¢gure shows the corresponding
ribbon structures.
Fig. 4. Di¡erent views of OFQ2 (the lower one rotated 90‡ counter-
clockwise, around the X axis, in relation to the upper one). The van
der Waals surfaces of atoms in side-chains are colored in light gray
(hydrophilic residues), dark gray (hydrophobic residues) or black
(charged residues; a negative (3) and a positive (+) sign, respec-
tively, are used to label Glu3 and Arg6).
FEBS 23646 8-5-00
P. Amodeo et al./FEBS Letters 473 (2000) 157^160 159
phobic and hydrophilic residues in di¡erent shades of gray. As
can be seen from this ¢gure, hydrophobic residues do not
cluster according to any known motif (amphiphilic helix,
Leu-zipper, coiled-coil) but are irregularly scattered along
the helix surface, forming one larger and two smaller hydro-
phobic pockets. This feature could explain the lack of struc-
ture for the peptide when the spectra were run in solvent
mixtures di¡erent from the helix-promoting mixture HFA/
water.
In our previous works [23] on short to medium-sized pep-
tides, the onset of helical structures in solvents with lower
structure-promoting ability than HFA/water mixtures is sys-
tematically associated with the presence of well de¢ned pat-
terns in the distribution of hydrophobic residues. In this re-
spect, HFA/water could protect the helix from a solvent
disruptive e¡ect derived from unfavorable solvation of hydro-
phobic groups, thus ‘restoring’ the helical propensity of the
peptide emerging from structure prediction calculation and
molecular mechanics in vacuum.
This distribution of hydrophobic residues in OFQ2 could
suggest close interaction of this peptide with a hydrophobic
core or, at least, complementary hydrophobic regions in the
intact precursor of the peptide.
4. Discussion
The role of OFQ2 in the control of pain is not yet estab-
lished with certainty, but a comparison of its primary and
secondary structure with those of other ‘pain peptides’ may
help to clarify the issue. OFQ2 shares some sequence similar-
ity with NC in the N-terminal sequence, Phe-Ser-Glu-Phe
versus Phe-Gly-Gly-Phe, and with dynorphin A for the pres-
ence of Phe in position four. Aromatic residues (Phe and Tyr)
in the N-terminal sequence of opioid and ORL1 peptides play
a major role in receptor binding and receptor activation [5,24].
Otherwise, there is little sequence similarity, e.g. dynorphin A
and NC owe their selectivity to the presence of several cati-
onic residues in the address domain, whereas OFQ2 has but
one cationic residue (Arg) in position six. It has been reported
that these cationic residues are important requirements for
selective receptor binding. The potent analgesic activity of
OFQ2 both spinally and supraspinally, not mediated by
opioid receptors (W, N, U and ORL1), hints that this new pep-
tide could interact with di¡erent receptors or according to
Pasternak et al. [10] it may activate downstream naloxone-
sensitive opioid mechanisms. Our structural data show that
the uniform distribution of hydrophobic residues along the
helix is consistent with the presence of a uniformly apolar
environment in vivo, such as that of the lipid phase of mem-
branes that hosts the transmembrane helices of ORL1 and
opioid receptors. It is tempting to suggest that OFQ2 interacts
with the transmembrane helices of a receptor of this kind in a
fashion similar to that proposed for L-endorphin [22].
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